synthesis. potential of inhibiting PCSK9 function(9-11). However, these therapeutic candidates require a 60 parenteral route of administration, rather than being orally bioavailable. Utilizing a phenotypic 61 screen for the discovery of small molecules that inhibit the secretion of PCSK9 into conditioned 62 media, we have recently identified a compound family that inhibits the translation of 63 PCSK9(12). However, the mechanism of translation inhibition exerted by these compounds 64 remains unknown. Herein we describe a more optimized small molecule, PF-06446846 that 65 demonstrates in vivo activity. We show that PF-06446846 induces the 80S ribosome to stall 66 while translating PCSK9. We further demonstrate using ribosome profiling that despite acting 67 through protein translation, a core cellular process, PF-06446846 is exceptionally specific, 68 affecting very few proteins. The PF-06446846 mechanism of action reveals a previously 69 unexpected potential to therapeutically modulate the human ribosome with small molecules as a 70 means to target previously "undruggable" proteins. 
74
The previously identified hit compound was adequate for initial in vitro characterization 75 but in vivo assessment required improvements in pharmacokinetic properties(12). The potency, 76 physicochemical properties and the off-target pharmacology associated with the hit compound 77 were improved by structural changes to two regions of the molecule. These efforts led to the 78 identification of compound PF-06446846 ( Fig. 1A) with properties suitable for both in vitro and 79 in vivo evaluation ( Fig. S1 and Table S1 ). The synthesis and physiochemical characterization of 
5
( Fig S1A) to PF-06446846 are Leu15-Leu20, residues 9-11 which include two tryptophan amino acids, and 109 residues 31-33 ( Fig. S10A-B analysis reveals that almost all of the change in expression levels occurs at the translation step
196
( Fig. 3G-I ). The two features present in the data at 10 minutes but not at one hour, the relative analysis using only reads aligning 3' to the stall site (Fig. 5A ). To estimate a 3' bound for the when data were analyzed using the same criteria as for the secretome (Fig. S9E-H To validate our approach, we tested the translational inhibitory activity of PF-06446846 259 for a set of the targets identified in the 1-hour datasets in HeLa-derived cell free translation 260 reactions. In the all but two cases, translation of constructs consisting of the predicted stall site 261 fused to luciferase was inhibited by PF-06446846 (Fig. 5J ). For the other two proteins, Midikine 262 and BCAP31, the translation of luciferase fusions to the full-length proteins was inhibited by PF-263 06446846 (Fig. 5K) . Four control sequences predicted not to be PF-06446846-sensitive were 264 inhibited at comparable levels as luciferase alone (Fig. 5L ).
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We next tested the translation inhibition of PF-06446846 towards four example "stall 267 sequences" identified only in the 10-minute dataset. PF-06446846 inhibited translation of all of 268 these transcripts only slightly more than luciferase alone (Fig. 5M) . These results indicate that were also identified using the D max approach (Fig. S14T ). For the hits identified using only 281 center-of-density analysis, VPS25 and TM2D3 had stalls but no decrease in downstream reads,
282
indicating that the stall was unlikely to result in a decrease in protein production ( Fig. S14P-Q) .
283
MAPRE1 did not have a clear stall site (Fig. S14R) . COX10 (Fig. S14S ) had a series of PF-284 06446846-induced stalls near the stop codon which would be difficult to detect using the D max 285 approach because of a lack of downstream reads to quantify. We also used center of density 286 analysis to confirm the bias for stalling near the 5' ends of the CDS by repeating the center of 287 density analyses omitting the first 50, 100 and 150 codons respectively (Fig. 6B-D) . In all cases, ribo-seq reads (Fig. 6E) . For all identified PF-06446846-sensitive sequences, the changes in 295 ribosome footprints, were due solely to changes at the level of translation (Fig. 6E ). We stalling near the N-terminus could impede initiation, thus lowering the overall initiation rate.
355
Evidence for "queued" ribosomes ( Fig. 1H-J) suggest impeding of initiation could occur for 356 stalls near the N-terminus. However, an impact on translation initiation could not explain the effects of more C-terminal stalling on CDH1 levels ( Fig. S9G-H 2176-2180 (1987) . percentage of reads aligning at or 5' to that codon. In all plots data from 1.5 µM PF-06446846
